KTC
AST

Kistler-Tiffany Companies’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Kistler-Tiffany Companies’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-208
Closed -$1K – 649
2014
Q4 		$1K Buy
+208
New +$837 ﹤0.01% 585

Other funds holding AST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
AIM
Allen Investment Management New York $8.43B AUM 20.31% 1-Year Est. Return

Kistler-Tiffany Companies's AST Position: Q1 2015 in Review

Kistler-Tiffany Companies sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2015, closing a stake of 208 shares — an estimated $1K sold.

Kistler-Tiffany Companies first reported a position in AST in Q4 2014 and held it in 1 quarter. The position peaked at $1K in Q4 2014. 39 funds tracked by Wall St. Rank hold AST as of Q1 2015.

  • Kistler-Tiffany Companies reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2015 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 208 Asterias Biotherapeutics Inc. Series A shares in Q1 2015, an estimated $1K.
  • Kistler-Tiffany Companies first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 1 quarter.
  • Kistler-Tiffany Companies's Asterias Biotherapeutics Inc. Series A position peaked at $1K in Q4 2014.
  • 39 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2015.

Based on Kistler-Tiffany Companies's 13F filing for Q1 2015, filed 6 May 2015.